MHRA green-lights Pfizer and AstraZeneca Covid vaccines for booster use

The UK medicines regulator has approved the use of a third dose of both the Pfizer and AstraZeneca Covid vaccines ahead of an expected announcement about booster jabs.

Both vaccines have been approved for the extra dose on an emergency use basis, the Medicines and Healthcare Products Regulatory Agency (MHRA) announced.

Related Article: England’s CNO to launch nursing strategy ‘later this year’

NHS England confirmed last week that they were awaiting final Joint Committee on Vaccination and Immunisation (JCVI) advice on when the programme will start and who exactly will be prioritised, and a statement is expected from the committee imminently.

Dr June Raine, MHRA chief executive said: ‘We are committed to getting safe and effective Covid-19 vaccines to the UK public. This means ensuring that existing Covid-19 vaccines can continue to be used in the most effective way possible. We know that a person’s immunity may decline over time after their first vaccine course.

‘I am pleased to confirm that the Covid-19 vaccines made by Pfizer and AstraZeneca can be used as safe and effective booster doses. This is an important regulatory change as it gives further options for the vaccination programme, which has saved thousands of lives so far.’

Related Article: More nursing apprenticeships and changes to student travel expenses

Dr Raine said it would be for the JCVI to advise on whether booster jabs should be given and if so which vaccines should be used.

She said: ‘We have in place a comprehensive safety surveillance strategy for monitoring the safety of all UK-approved COVID-19 vaccines and this surveillance will include booster jabs.’

Related Article: Nurses given ‘range of leadership opportunities’ in NHS 10-year plan

The NHS had previously been mobilising for the two-stage booster programme to begin from 6 September, alongside flu vaccinations but that was delayed.

Practices have already been told they can start vaccinating immunosuppressed patients with a third dose, although JCVI stressed that was a third first-round dose, rather than a booster shot.